Expression of BDNF-Associated lncRNAs in Treatment-Resistant Schizophrenia Patients

Badrlou, Elham; Ghafouri‐Fard, Soudeh; Omrani, Mir Davood; Neishabouri, Seyedeh Morvarid; Arsang‐Jang, Shahram; Pouresmaeili, Farkhondeh

doi:10.1007/s12031-020-01772-9

Cited by 11 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, long non-coding RNA (lncRNAs) also modulate levels of individual protein-coding transcripts, acting through a variety of mechanisms, including the sponging of miRNAs [ 41 ], generation of new miRNAs [ 42 ], induction of genomic imprinting [ 43 ], and so on. Badrlou et al [ 44 ] found that the levels of BDNF mRNA and three BDNF-associated lncRNAs (BDNF-AS, MIR137HG, and MIAT) in peripheral blood could discriminate SZ patients from normal subjects with a diagnostic power of 71%, 72%, 67%, and 68%, respectively. Increasing evidence supports the potential involvement of lncRNAs in SZ [ 45 , 46 , 47 ].…”

Section: Discussionmentioning

confidence: 99%

Deregulatory miRNA-BDNF Network Inferred from Dynamic Expression Changes in Schizophrenia

Baranova

Zhang

2022

Brain Sciences

View full text Add to dashboard Cite

(1) Background: Brain-derived neurotrophic factor (BDNF) is one of the promising risk genes for schizophrenia (SZ), a disease with prominent dysregulation of miRNA networks. Here, we present a study of miRNA-BDNF co-expression changes in peripheral blood of SZ patients. (2) Methods: The expression levels of the BDNF mRNA and three validated binding miRNAs—miR-124-3p, miR-132-3p, and miR-206—were quantified in the blood of 48 healthy controls and 32 SZ patients before and after 12 weeks of treatment. The co-expression patterns were evaluated in the three groups. (3) Results: The expression levels of BDNF were significantly downregulated in SZ patients compared to the controls. After the treatment, the expression levels of BDNF were upregulated, while the expression levels of the three miRNAs were downregulated. Co-expression analyses showed positive correlations of this network in the SZ patients, while weak negative correlations were observed in the healthy controls. After the 12-week treatment, the overall correlation between BDNF and the three miRNAs reached the levels comparable to the healthy controls. (4) Conclusions: Our findings suggest the involvement of the miRNA-BDNF network in the onset and treatment of SZ.

show abstract

Section: Discussionmentioning

confidence: 99%

Deregulatory miRNA-BDNF Network Inferred from Dynamic Expression Changes in Schizophrenia

Baranova

Zhang

2022

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…Neurodevelopmental models have proposed that synaptic function is negatively affected when BDNF concentrations are reduced, altering neurotransmission and giving rise to symptoms seen in schizophrenia [ 68 , 69 ]. Badrlou and colleagues [ 38 ] found higher expression levels of BDNF as well as the BDNF -associated lncRNA PKNY in TRS patients. Zhang and colleagues [ 39 ] reported an increased incidence of TRS in minor allele carriers of multiple BDNF SNPs.…”

Section: Resultsmentioning

confidence: 99%

Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review

Ying

Chew

McIntyre

et al. 2023

Genes

View full text Add to dashboard Cite

Treatment-resistant schizophrenia (TRS) is often associated with severe burden of disease, poor quality of life and functional impairment. Clozapine is the gold standard for the treatment of TRS, although it is also known to cause significant side effects in some patients. In view of the burgeoning interest in the role of genetic factors in precision psychiatry, we conducted a scoping review to narratively summarize the current genetic factors associated with TRS, clozapine resistance and side effects to clozapine treatment. We searched PubMed from inception to December 2022 and included 104 relevant studies in this review. Extant evidence comprised associations between TRS and clozapine resistance with genetic factors related to mainly dopaminergic and serotoninergic neurotransmitter systems, specifically, TRS and rs4680, rs4818 within COMT, and rs1799978 within DRD2; clozapine resistance and DRD3 polymorphisms, CYP1A2 polymorphisms; weight gain with LEP and SNAP-25 genes; and agranulocytosis risk with HLA-related polymorphisms. Future studies, including replication in larger multi-site samples, are still needed to elucidate putative risk genes and the interactions between different genes and their correlations with relevant clinical factors such as psychopathology, psychosocial functioning, cognition and progressive changes with treatment over time in TRS and clozapine resistance.

show abstract

“…Another study, involving a small cohort of 50 SZ patients and 50 normal individuals, found no statistically significant differences in MIAT expression levels between the two groups [ 174 ]. However, the study reported that the diagnostic accuracy of the MIAT gene to differentiate between SZ patients and controls was 68% [ 174 ].…”

Section: Myocardial Infarction Associated Transcript ( Miat...mentioning

confidence: 99%

MIAT LncRNA: A multifunctional key player in non-oncological pathological conditions

Zeinelabdeen,

Abaza,

Yasser

et al. 2024

Non-coding RNA Research

View full text Add to dashboard Cite

Expression of BDNF-Associated lncRNAs in Treatment-Resistant Schizophrenia Patients

Cited by 11 publications

References 36 publications

Deregulatory miRNA-BDNF Network Inferred from Dynamic Expression Changes in Schizophrenia

Deregulatory miRNA-BDNF Network Inferred from Dynamic Expression Changes in Schizophrenia

Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review

MIAT LncRNA: A multifunctional key player in non-oncological pathological conditions

Contact Info

Product

Resources

About